CCRM Enterprises invests in early-stage ventures and projects developing therapeutics and enabling technologies. Through an extensive network of investors, it can bring together risk capital to support these early-stage ventures as they scale up along the development pathway. By tapping into CCRM’s manufacturing infrastructure and expertise, CCRM Enterprises provides capital-efficient support to accelerate and de-risk these high potential, early-stage ventures, further enabling the development of an advanced therapies ecosystem.
Partnering with start-ups
CCRM works with start-ups to ensure they have the necessary people, facilities and funding. Partnering with start-ups may take the form of direct investment, licensing of technologies to CCRM, or asset co-development.
The core components of our offering to start-ups include:
Development and manufacturing infrastructure
Counsel from an expert Investment Board, composed of scientists and venture capitalists
Connection to network and participation in exclusive events
A unique approach as compared to traditional venture capital (VC) groups
Partnering with investors
CCRM also works with other investors in partnerships that may take the form of co-investment in current opportunities, creation of co-branded biotech funds, or direct investments in CCRM’s company creation engine.
CCRM can provide investors with the following: access to local emerging companies or opportunities coming from CCRM’s international hubs; access to our in-house specialized scientific team to inform decisions; and, the potential for engagement with CCRM’s incubating companies.